Y-mAbs to Present at the Oppenheimer 35ᵗʰ Annual Life Sciences Conference

Rhea-AI Summary

Y-mAbs Therapeutics (Nasdaq: YMAB), a commercial-stage biopharmaceutical company specializing in radioimmunotherapy and antibody-based therapeutic products for cancer treatment, has announced its participation in the Oppenheimer 35th Annual Life Sciences Conference.

The company's President and CEO, Michael Rossi, will engage in a fireside chat scheduled for Tuesday, February 11, 2025, at 4:40 p.m. ET. Investors and interested parties can access a live webcast of the presentation through the Events section on Y-mAbs' investor relations website at ir.ymabs.com. The presentation recording will remain available for replay on the website for 30 days following the event.

NEW YORK, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced that Michael Rossi, President and Chief Executive Officer, will participate in a fireside chat at the Oppenheimer 35^th Annual Life Sciences Conference on Tuesday, February 11, 2025 at 4:40 p.m. ET.

A live webcast will be available under the Events section of the Company’s investor relations website at ir.ymabs.com. The webcast will be archived and available for replay for 30 days after the event.

About Y-mAbs
Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, radioimmunotherapy and antibody-based therapeutic cancer products. The Company’s technologies include its investigational Self-Assembly DisAssembly (“SADA”) Pretargeted Radioimmunotherapy Platform (“PRIT”) and bispecific antibodies generated using the Y-BiClone platform. The Company’s broad and advanced product pipeline includes the anti-GD2 therapy DANYELZA® (naxitamab-gqgk), the first FDA-approved treatment for patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow after a partial response, minor response, or stable disease to prior therapy.

Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, statements about our business model, including financial outlook for 2024 and beyond.Words such as ‘‘anticipate,’’ ‘‘believe,’’ “contemplate,” ‘‘continue,’’ ‘‘could,’’ ‘‘estimate,’’ ‘‘expect,’’ “hope,” ‘‘intend,’’ ‘‘may,’’ ‘‘might,’’ ‘‘plan,’’ ‘‘potential,’’ ‘‘predict,’’ ‘‘project,’’ ‘‘should,’’ ‘‘target,’’ “will,” ‘‘would’,’ “guidance,” “goal,” “objective,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company’s business is subject to risks and uncertainties affecting the Company including those described in the “Risk Factors” section included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and the Company’s Quarterly Report on Form 10-Q for the quarterly periods ended March 31, 2024, and September 30, 2024, and future filings and reports by the Company. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

SADA^®, SADA PRIT™, DANYELZA^® and Y-mAbs^® are registered trademarks of Y-mAbs Therapeutics, Inc.

Investor Contact:
Courtney Dugan
VP, Head of Investor Relations
cdu@ymabs.com

FAQ

When is Y-mAbs (YMAB) presenting at the Oppenheimer Life Sciences Conference 2025?

Y-mAbs will present at the Oppenheimer Conference on Tuesday, February 11, 2025, at 4:40 p.m. ET.

How can investors watch Y-mAbs' (YMAB) Oppenheimer Conference presentation?

Investors can watch the presentation through a live webcast available in the Events section of Y-mAbs' investor relations website at ir.ymabs.com.

How long will Y-mAbs' (YMAB) Oppenheimer Conference presentation be available for replay?

The webcast will be archived and available for replay for 30 days after the event.

What type of presentation will Y-mAbs (YMAB) deliver at the Oppenheimer Conference?

Y-mAbs' President and CEO Michael Rossi will participate in a fireside chat format presentation.

What is Y-mAbs' (YMAB) primary business focus according to the announcement?

Y-mAbs is a commercial-stage biopharmaceutical company focused on developing and commercializing radioimmunotherapy and antibody-based therapeutic products for cancer treatment.